Anixa Biosciences ANIX 深 沪
交易中 06-30 10:41:26 美东时间
2.8054
-0.045
-1.56%
华盛通- 最 高2.90
- 今 开2.84
- 成交量 9.75万股
- 最 低 2.74
- 昨 收 2.85
- 总市值 9544.83万
- 52周最高 5.4566
- 市盈率 静 --
- 换手率 0.29%
- 52周最低 2.32
- 委 比 -69.10%
- 总股本 3402.31万
- 历史最高 8.09
- 量 比 1.66
- 振 幅 5.61%
- 历史最低 1.33
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Anixa Biosciences Announces Its Breast Cancer Vaccine's Final Phase 1 Data Shows All Major Primary Endpoints Met, Protocol-Defined Immune Responses Generated In 74% Of Participants
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its two clinical-stage immunotherapy programs were presented at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy sympos...
06-26 21:13
Anixa Biosciences Q2 EPS $(0.07) Beats $(0.09) Estimate
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 22.22 percent increase over losses of $(0.09) per share from the same period last year.
06-11 05:31
Anixa Biosciences Secures Canadian Patent Allowance For AMHR2-Targeting Ovarian Cancer Vaccine Technology
Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancerSAN JOSE, Calif., June 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or
06-01 21:10
Anixa Biosciences Announces Its Data From Phase 1 Clinical Study Of Liraltagene Autoleucel Demonstrates No Dose-Limiting Toxicities To Treat Recurrent Ovarian Cancer
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations from its ongoing Phase 1
05-11 21:02
Anixa reports updated survival data from Phase 1 lira-cel ovarian cancer CAR-T trial
Anixa reports updated survival data from Phase 1 lira-cel ovarian cancer CAR-T trial Anixa Biosciences reported updated survival observations from its ongoing Phase 1 trial of lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer. Results were presented May 7, 2026, at International
05-11 20:55
Anixa Biosciences Receives Patent From Mexican Institute Of Industrial Property For Its Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial Property (IMPI)
04-29 21:13
Anixa Biosciences Reports Survival Data For Lira-cel In Phase 1 Trial At ISCT 2026 Conference
Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trialSAN JOSE, Calif., April 22, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a
04-22 20:47
Anixa to present ovarian cancer CAR-T trial update at ISCT annual meeting
Anixa to present ovarian cancer CAR-T trial update at ISCT annual meeting Anixa Biosciences to present Phase 1 data update for ovarian cancer CAR-T candidate lira-cel at ISCT 2026 Annual Meeting on May 6-9, 2026, in Dublin. Presentation covers trial design, objectives, current status for lira-cel in
04-22 20:45
Anixa CEO to present at Water Tower Research Insights Conference
Anixa CEO to present at Water Tower Research Insights Conference Anixa Biosciences scheduled to present at Water Tower Research Insights Conference on April 14, 2026 at 12:30 p.m. ET. Session expected to highlight Phase 1 breast cancer vaccine results, including protocol-defined immune responses in
04-07 20:55
Anixa Biosciences To Present Ovarian Cancer CAR-T Therapy Clinical Trial At 2026 SGO Annual Meeting
Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-cel trial statusSAN JOSE, Calif., March 30, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")
03-30 21:09
